In March 2023, during an off-site leadership meeting at Moderna, CEO Stéphane Bancel asked executives whether any of them had expected the company’s experimental cancer vaccine to succeed. Only a few — including company president Stephen Hoge — indicated they had. Hoge later told STAT that even company leaders had not initially believed the results and that it took time before they felt the findings were real.
The vaccine program had earlier shown promise in mid-stage testing, but doubt about the feasibility of an mRNA-based cancer vaccine persisted both inside and outside Moderna. The project had long been regarded as a potential breakthrough that many observers found hard to accept.
Moderna and Merck publicly revealed late-stage results in August 2026 indicating that their mRNA cancer vaccine reduced the odds that melanoma — after surgical removal — would return or spread. The public announcement cited a randomized trial enrolling 1,137 volunteers.
The STAT excerpt reports the topline finding that recurrence or spread was reduced in the vaccinated group. It notes that until the companies’ announcement, outside investors and many observers had been skeptical, and that some experts urged caution pending the release of fuller data.
The therapy discussed in the article is named intismeran autogene. The treatment employs mRNA technology, an approach that has been at the center of both intense enthusiasm and lingering skepticism since the success of mRNA platforms in other areas.
Throughout the coverage, the vaccine is framed as a major test of whether mRNA approaches can be harnessed effectively to prevent recurrence of an established cancer, rather than to prevent infectious disease.
According to the reporting, executive reactions at Moderna evolved from disbelief to cautious optimism as trial results emerged. Stéphane Bancel’s question at the March 2023 meeting — and the limited number of executives who initially believed in success — underscores how unexpected the positive findings felt internally.
Investor sentiment prior to the announcement had been unfavorable toward Moderna’s stock, reflecting broader skepticism about the program. After the topline results were released, some observers urged waiting for full trial data before revising judgments about the vaccine’s effectiveness and implications.
The STAT excerpt emphasizes that the companies released top-line results and that some researchers and longtime skeptics of mRNA technology urged restraint until complete data were available. The story notes that while top-line results from major drugmakers are rarely reversed, comprehensive safety data, detailed efficacy metrics, subgroup analyses, and full study methods were not included in the excerpted material.
As such, the excerpt makes clear that final clinical and regulatory conclusions depend on the forthcoming full dataset and independent analysis. Specific numerical estimates of efficacy, confidence intervals, adverse-event profiles, duration of follow-up, and other protocol details were not reported in the available portion of the article.
This STAT story was published on Aug. 24, 2026, and is presented as a STAT+ exclusive. The available excerpt indicates that much of the in-depth reporting and analysis is behind the STAT+ subscriber paywall. The excerpted material includes quotes and narrative about internal reactions and the public announcement, but it does not include the full dataset, detailed trial methodology, or complete safety and efficacy tables.
Readers seeking the full article and the reporters’ detailed account, including any additional facts or data, would need access to the complete STAT+ piece. The excerpt explicitly notes the subscription requirement and that additional specifics were not reported in the provided content.
Note on source limitations
This rewritten report is based solely on the excerpted STAT News text provided. The source excerpt reports the topline outcome, the trial size (1,137 volunteers), the vaccine name (intismeran autogene), key company figures, and the paywalled status of the full article. It does not include numeric efficacy results, safety data, detailed trial design, or full investigator commentary; those details were not reported in the source excerpt and therefore are not included here.